

## Your Comments are Important to Us

---

To improve the high standards established for this publication, the Alberta Health Expert Committee on Drug Evaluation and Therapeutics would like to offer you an opportunity for input. Should you have any concerns and/or suggestions concerning product listings or criteria for coverage of products available via special authorization, etc. please let us know. If you are writing in support of a product listing change or a revision to the special authorization criteria for coverage, you must provide evidence in support of your comments from the peer-reviewed scientific literature. In order to meet the expectations of stakeholders relative to objectivity and transparency, all individuals providing comments are required to advise the Expert Committee of any potential conflicts of interest below (please check appropriate box):

**Please note: this is not a mechanism for an appeal for a specific patient.**

**Conflict of Interest:**       Yes     No

*If Yes, please indicate the nature of the potential conflict of interest below:*

---



---

*Please provide your comments in the space provided below:*

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

**Contact Information:**

**Name and Address:** \_\_\_\_\_

**Phone/Fax:** \_\_\_\_\_

Please print form and mail/fax to:

**Alberta Health Expert Committee on Drug Evaluation and Therapeutics**  
*c/o Manager*  
*Scientific and Research Services*  
 Alberta Blue Cross  
 10009 108 Street NW  
 Edmonton, Alberta T5J 3C5  
 FAX to: (780) 498-3534

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.